5-α Reductase Inhibitors: How to Select the Right Agent Within the Class

What Are 5-α Reductase Inhibitors and How Do They Work?

5-α reductase inhibitors block the enzyme family that converts testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for prostate epithelial growth and androgenetic alopecia. Reducing DHT causes prostate epithelial apoptosis, measurable gland shrinkage, and, in genetically susceptible hair follicles, a slowdown in miniaturization. The class contains exactly two FDA-approved small molecules: finasteride and dutasteride.

The Three Isoenzymes and Why They Matter

Three distinct 5-α reductase isoenzymes exist (type 1, type 2, type 3), distributed differently across tissues. Type 2 predominates in prostate stroma, genital skin, and liver. Type 1 is the dominant isoenzyme in sebaceous glands and liver, contributing meaningfully to total circulating DHT. Type 3 activity is lower and its clinical significance is not yet established.

Finasteride is a selective, competitive inhibitor of type-2 5-α reductase. Dutasteride inhibits both type-1 and type-2 isoenzymes with sub-nanomolar affinity for each. This dual inhibition is why dutasteride suppresses serum DHT by approximately 90 to 95%, compared with roughly 70% for finasteride. The difference in scalp DHT suppression is even more pronounced because type-1 activity is substantial in scalp sebaceous glands.

Pharmacokinetics: A Clinically Relevant Gap Between the Two Agents

Finasteride carries a half-life of 5 to 6 hours in younger men (extending to 8 hours in men over 70), yet its tissue-level enzyme inhibition persists for days after a single dose. The enzyme-bound complex is essentially irreversible on a pharmacological timescale. Dutasteride has a terminal half-life of 3 to 5 weeks, meaning steady-state DHT suppression accumulates over months and drug levels persist long after discontinuation. For patients concerned about reversibility of side effects, this kinetic difference deserves explicit counseling.

FDA-Approved Indications and Doses

Each agent carries specific, dose-dependent FDA labels. Prescribing outside those labels is common in clinical practice but requires documentation of rationale.

Finasteride: Two Doses, Two Indications

• Finasteride 5 mg (Proscar): FDA-approved for symptomatic BPH (alone or with doxazosin) in men with an enlarged prostate. The Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) demonstrated a 55% reduction in acute urinary retention risk and a 34% reduction in surgical intervention over 4 years with finasteride 5 mg vs. Placebo. PLESS showed mean prostate volume decreased 18% from baseline at 4 years in the finasteride group vs. A 14% increase in placebo.
• Finasteride 1 mg (Propecia): FDA-approved for male androgenetic alopecia (vertex and anterior mid-scalp). The key trials (N=1,553 combined) showed 83% of men maintained or increased hair count at 2 years vs. 28% on placebo. At 5 years, men on finasteride 1 mg demonstrated a mean increase of 277 hairs per 1-inch-diameter circle vs. A loss of 100 hairs in the placebo group.

Dutasteride: BPH and Off-Label Hair Loss

• Dutasteride 0.5 mg (Avodart): FDA-approved for symptomatic BPH as monotherapy or combined with tamsulosin 0.4 mg (Jalyn). The CombAT trial (N=4,844, 4 years) compared dutasteride monotherapy, tamsulosin monotherapy, and the combination. Combination therapy reduced the relative risk of acute urinary retention by 67.8% and BPH-related surgery by 70.6% vs. Tamsulosin alone. Dutasteride monotherapy reduced prostate volume by 27.3% at 4 years.
• Dutasteride 0.5 mg (off-label, androgenetic alopecia): Not FDA-approved for hair loss in the US, though it carries approval for this indication in South Korea and Japan. A randomized trial (N=153) found dutasteride 0.5 mg produced significantly greater increases in target-area hair counts than finasteride 5 mg at 24 weeks. Dutasteride 0.5 mg outperformed finasteride 5 mg on photographic assessments at 24 weeks (P<0.001). Prescribers using it off-label for alopecia should document this clearly.

Selecting the Agent: A Clinical Decision Framework

The choice between finasteride and dutasteride is not arbitrary. Five clinical variables most reliably guide the selection:

Variable 1: Prostate Volume

Men with prostate volumes above 40 mL derive greater absolute benefit from 5ARIs than men with smaller glands, because a larger epithelial compartment means more DHT-dependent tissue to shrink. AUA BPH Guidelines recommend 5ARIs for men with prostate volumes >30 mL or PSA >1.5 ng/mL. For prostate volumes above 60 mL, the deeper DHT suppression from dutasteride may yield proportionally more shrinkage. The REDUCE trial (N=8,231) used dutasteride 0.5 mg specifically because of its superior DHT suppression in a chemoprevention context. REDUCE found a 22.8% relative risk reduction in prostate cancer detection on biopsy at 4 years with dutasteride vs. Placebo.

Variable 2: Hair Loss as a Co-Indication

When a man has both BPH and androgenetic alopecia, the prescribing calculus changes. Finasteride 1 mg produces only partial scalp DHT suppression because type-1 isoenzyme continues to generate DHT in sebaceous glands. Type-1 5-α reductase accounts for roughly 30 to 40% of scalp DHT synthesis, meaning finasteride's type-2-only blockade leaves a substantial androgenic signal intact at the follicle. Dutasteride's dual inhibition suppresses scalp DHT more completely, which correlates with better hair-count outcomes in head-to-head data. A patient with moderate-to-severe androgenetic alopecia and BPH is a reasonable candidate for dutasteride 0.5 mg, with off-label hair loss discussed explicitly.

Variable 3: PSA Interpretation

Both agents suppress serum PSA. Finasteride 5 mg reduces PSA by approximately 50% after 6 months; dutasteride 0.5 mg suppresses PSA by a similar 50% at 6 months, though some studies show marginally greater suppression at 24 months. The FDA label for both agents states that any confirmed PSA increase in a man on a 5ARI, even when within the normal range, should be evaluated for prostate cancer. Clinicians should double the measured PSA to estimate the untreated equivalent, a practice endorsed by the 2023 AUA/SUFU guidelines. A man whose PSA rises despite 5ARI therapy warrants prompt investigation regardless of absolute value.

Variable 4: Baseline Sexual Function

Sexual side effects, reduced libido, erectile dysfunction, ejaculatory dysfunction, occur in approximately 3 to 8% of men in registration trials for both agents. The MTOPS trial (N=3,047) reported sexual adverse events in 5.7% of finasteride-plus-doxazosin patients vs. 2.1% with doxazosin alone over 4.5 years. Direct head-to-head comparisons of finasteride vs. Dutasteride on sexual endpoints show no consistent difference in incidence. For patients with pre-existing erectile dysfunction or low libido, a frank conversation about baseline status before starting therapy is essential, not because one agent is safer, but because attributing new symptoms accurately depends on documented pretreatment function.

Post-finasteride syndrome (PFS), characterized by persistent sexual, neurological, and psychological symptoms after discontinuation, remains a contested entity. The FDA updated finasteride labels in 2012 to include persistent sexual side effects after discontinuation. The prevalence is uncertain; most published case series are small and uncontrolled. Prescribers should address the topic directly during informed consent.

Variable 5: Drug Half-Life and Patient Reliability

Dutasteride's 3-to-5-week half-life means missed doses have minimal clinical impact on DHT suppression. A patient with inconsistent medication adherence may achieve more stable DHT suppression with dutasteride than with finasteride. The tradeoff: if a patient develops a significant adverse effect, dutasteride's effects persist for months after stopping, whereas finasteride clears faster and DHT returns to near-baseline within weeks of discontinuation. Serum DHT returns to baseline within 14 days of stopping finasteride in most men.

Evidence From the Major Trials

MTOPS: Combination vs. Monotherapy for BPH

The Medical Therapy of Prostatic Symptoms trial (MTOPS, N=3,047, mean follow-up 4.5 years) tested doxazosin, finasteride 5 mg, combination therapy, and placebo. Combination therapy reduced the risk of overall clinical progression by 66% vs. Placebo (P<0.001), compared with 39% for doxazosin alone and 34% for finasteride alone. Finasteride (but not doxazosin) reduced the long-term risk of acute urinary retention and invasive therapy, establishing that 5ARIs modify the disease course, not just symptoms.

CombAT: Dutasteride Sets the BPH Evidence Bar

CombAT (N=4,844, 4 years) is the largest trial specifically designed with dutasteride as the 5ARI. Men with prostate volumes >30 mL and baseline PSA between 1.5 and 10 ng/mL were enrolled; combination dutasteride plus tamsulosin reduced IPSS scores by 6.3 points from baseline at year 4 vs. 4.9 points for dutasteride alone. The absolute difference was modest but statistically significant, supporting combination therapy in men at higher risk of progression.

PLESS: Long-Term Finasteride Safety and Efficacy

PLESS (N=3,040, 4 years) remains the foundational finasteride BPH trial. Sexual side effects were reported by 15.8% of finasteride patients vs. 13.6% of placebo patients. The difference in sexual side effects between finasteride and placebo was statistically significant only for decreased libido (6.4% vs. 3.4%, P<0.001) and ejaculation disorder (7.7% vs. 1.7%, P<0.001). Erectile dysfunction rates were not statistically different from placebo, a finding often overlooked in clinical counseling.

Hair Loss Trials: Finasteride 1 mg and the Dutasteride Comparison

The registration trials for finasteride 1 mg used standardized hair-count photography over 5 years and are among the most rigorously designed alopecia studies conducted. At 2 years, 83% of men on finasteride 1 mg maintained or improved hair count vs. 28% on placebo (P<0.001 for all efficacy endpoints). The GlaxoSmithKline head-to-head trial (N=153) comparing dutasteride 0.5 mg to finasteride 5 mg in androgenetic alopecia found dutasteride superior on both target-area hair count and photographic global assessment at 24 weeks. Mean target-area hair count increased 12.2 hairs with dutasteride 0.5 mg vs. 7.1 hairs with finasteride 5 mg at 24 weeks.

Special Populations and Contraindications

Pregnancy and Women of Childbearing Potential

Both agents are classified FDA Category X for pregnancy. Finasteride and dutasteride inhibit virilization of a male fetus; even skin absorption from crushed tablets or semen exposure is a theoretical risk during the first trimester. Women who are pregnant or may become pregnant must not handle crushed or broken finasteride tablets. Dutasteride capsules should not be handled by pregnant women at all, given dutasteride's lipophilicity and skin penetration. The FDA label for dutasteride explicitly warns against handling by women of childbearing potential.

Hepatic Impairment

Both agents are extensively metabolized by CYP3A4 in the liver. Dutasteride is metabolized to three active metabolites via CYP3A4 and CYP3A5; the manufacturer contraindicates its use in patients with moderate-to-severe hepatic impairment. Finasteride is similarly hepatically metabolized, and dose adjustments or avoidance are appropriate in significant hepatic disease, though the prescribing label for finasteride does not specify a formal contraindication. Use clinical judgment and liver function data.

Pediatric Use

Neither agent is approved for use in patients under 18. Use in adolescent males with premature androgenetic alopecia is off-label and requires a detailed risk-benefit discussion, particularly given the unresolved concerns about post-finasteride syndrome and the potential impact on sexual development.

Monitoring and Follow-Up Protocol

Structured monitoring is the same for both agents in the BPH setting:

• PSA at baseline: Document pre-treatment PSA. Any value obtained after starting a 5ARI requires the doubling correction.
• PSA at 3 to 6 months: Establish the new on-treatment baseline. The 2023 AUA/SUFU guidelines recommend PSA monitoring every 1 to 2 years once stable on 5ARI therapy.
• IPSS reassessment at 3, 6, and 12 months: The International Prostate Symptom Score gives an objective marker of treatment response. Symptom improvement typically begins at 3 months; maximum effect takes 6 to 12 months.
• Prostate volume by transrectal ultrasound or MRI: Not required for routine monitoring but useful when clinical response is unclear or PSA trends unexpectedly.
• Sexual side effects screen at each visit: Brief structured questioning (IIEF or similar) documents any treatment-attributable change. The IIEF-5 (Sexual Health Inventory for Men) score provides a validated, five-question baseline before prescribing either agent.

For androgenetic alopecia, reassess response at 6 and 12 months with standardized photography. Patients not responding to finasteride 1 mg at 12 months may be candidates for dose escalation to 5 mg or a switch to off-label dutasteride 0.5 mg, with documentation of rationale.

Summary Decision Table: Finasteride vs. Dutasteride

| Clinical Scenario | Preferred Agent | Rationale | |---|---|---| | BPH, prostate 30 to 60 mL, no hair loss concern | Finasteride 5 mg | Sufficient efficacy; FDA-approved; lower cost | | BPH, prostate >60 mL or high PSA | Dutasteride 0.5 mg | Deeper DHT suppression; greater volume reduction | | BPH requiring combination therapy | Dutasteride 0.5 mg + tamsulosin 0.4 mg (Jalyn) | CombAT data; FDA-approved combination | | Male androgenetic alopecia (standard) | Finasteride 1 mg | FDA-approved; 5-year efficacy data | | Androgenetic alopecia, suboptimal response to finasteride | Dutasteride 0.5 mg (off-label) | Superior scalp DHT suppression; head-to-head data | | BPH plus moderate-to-severe androgenetic alopecia | Dutasteride 0.5 mg | Dual benefit; document off-label hair indication | | Unreliable medication adherence | Dutasteride 0.5 mg | 3-to-5-week half-life buffers missed doses | | Patient prioritizing rapid reversibility | Finasteride 5 mg | DHT returns to baseline within ~14 days of stopping | | Moderate-to-severe hepatic impairment | Avoid dutasteride; use caution with finasteride | CYP3A4 metabolism; dutasteride contraindicated |